Amino-pyrimidine skeletal muscle modulators

Patent metadata

Field	Value
Publication number	US-10765624-B2
Application number	US-201916352626-A
Country	US
Kind code	B2
Filing date	Mar 13, 2019
Priority date	Apr 23, 2010
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

First claim

What is claimed is:

1. A compound of formula

2. A pharmaceutical composition comprising a compound of claim 1 .

3. A pharmaceutical composition comprising a compound of formula

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient selected from the group consisting of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, and magnesium carbonate.

4. The pharmaceutical composition of claim 3 , further comprising one or more wetting agent, emulsifying agent, solubilizing agent, pH buffering agent, or any combination thereof.

5. The pharmaceutical composition of claim 3 , further comprising sodium acetate, sodium citrate, a cyclodextrine derivative, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, or any combination thereof.

6. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition comprises from about 0.5% to about 50% by weight of the compound of formula

7. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a powder, a liquid, a suspension, a suppository, or an aerosol.

8. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is in the form of a tablet.

9. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is in the form of a suspension.

10. A method for treating a disease or condition selected from the group consisting of neuromuscular disorders, conditions of muscle wasting, muscular myopathies, rehabilitation-related deficits, muscle atrophy and fatigue, metabolic syndrome, chronic fatigue syndrome, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), myasthenia gravis, peripheral vascular disease, peripheral arterial disease, chronic pulmonary obstructive disorder (COPD), heart failure, frailty, and obesity, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 3 .

11. The method of claim 10 , wherein the disease or condition is Amyotrophic Lateral Sclerosis (ALS).

12. The method of claim 10 , wherein the disease or condition is Spinal Muscular Atrophy (SMA).

13. The method of claim 10 , wherein the disease or condition is myasthenia gravis.

14. The method of claim 10 , wherein the disease or condition is peripheral vascular disease or peripheral arterial disease.

15. The method of claim 10 , wherein the disease or condition is chronic pulmonary obstructive disorder (COPD).

16. The method of claim 10 , wherein the disease or condition is heart failure.

17. The method of claim 10 , wherein the disease or condition is frailty.

Assignees

• Cytokinetics Inc

Inventors

• Yang Zhe
• Muci Alex R
• Warrington Jeffrey
• Bergnes Gustave
• Morgan Bradley P
• Chuang Chihyuan
• Romero Antonio
• Collibee Scott
• Qian Xiangping
• Lu Pu-Ping

Classifications

• C07D471/04

  Ortho-condensed systems · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title